Study of the Day: Even Low Doses of Sleeping Pills Triple Death Risk

More

Common hypnotic drugs like Ambien, Sonata, and Lunesta may significantly increase mortality and cancer risk, new research suggests.

main Henrik Winther Andersen shutterstock_21717391.jpg

PROBLEM: In 2010, nearly one in 10 adults in the U.S. took sleeping pills. But how safe are they?

METHODOLOGY: Researchers at the Scripps Clinic Sleep Center tracked the survival of 10,529 people who were prescribed sleeping pills for an average of 2.5 years. They compared these subjects, whose average age was 54, to 23,676 people who had not been prescribed sleeping pills over the same period. They also adjusted the data to account for age, gender, smoking, body mass index, ethnicity, marital status, alcohol use, and previously diagnosed cancer.

Some of the drugs tested in the trial were temazepam (Restoril), zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata).

RESULTS: Those prescribed fewer than 18 doses of sleeping pills a year were more than 3.5 times as likely to die as those in the control group. Moreover, the risk of death of moderate (18 to 132 doses) and heavy users (132+ doses) were four and five times greater than that of non-users, indicating that the risk level rose in tandem with increasing doses. Heavy users were also at higher risk of developing several types of cancer.

CONCLUSION: Sleeping pills are associated with a more than threefold increase in mortality risk, even if seldom used.

IMPLICATION: Alternatives to hypnotic drugs for the treatment of insomnia may be warranted, the authors say in a statement. Their journal editor, Trish Groves, agrees: "Although the authors have not been able to prove that sleeping pills cause premature death, their analyses ... raise important concerns and questions about the safety of sedatives and sleeping pills."

SOURCE: The full study, "Hypnotics' Association With Mortality or Cancer: A Matched Cohort Study," is published in the journal BMJ Open.

Image: Henrik Winther Andersen/Shutterstock.

Jump to comments
Presented by

Hans Villarica writes for and produces The Atlantic's Health channel. His work has appeared in TIME, People Asia, and Fast Company.

Get Today's Top Stories in Your Inbox (preview)

Adventures in Legal Weed

Colorado is now well into its first year as the first state to legalize recreational marijuana. How's it going? James Hamblin visits Aspen.


Elsewhere on the web

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register. blog comments powered by Disqus

Video

Adventures in Legal Weed

Colorado is now well into its first year as the first state to legalize recreational marijuana. How's it going? James Hamblin visits Aspen.

Video

What Makes a Story Great?

What makes a story great? The storytellers behind House of CardsThis American LifeThe Moth, and more reflect on the creative process.

Video

Tracing Sriracha's Origin to Thailand

Ever wonder how the wildly popular hot sauce got its name? It all started in Si Racha.

Video

Where Confiscated Wildlife Ends Up

A government facility outside of Denver houses more than a million products of the illegal wildlife trade, from tigers and bears to bald eagles.

Video

Is Wine Healthy?

James Hamblin prepares to impress his date with knowledge about the health benefits of wine.

Video

The World's Largest Balloon Festival

Nine days, more than 700 balloons, and a whole lot of hot air

Writers

Up
Down

More in Health

Just In